Unlocking Nicotinic Selectivity via Direct C‒H Functionalization of (−)-Cytisine

Hugo Rego Campello, Silvia G. Del Villar, Aurelien Honraedt, Teresa Minguez, A.Sofia Oliviera, Kara E. Ranaghan, Deborah Shoemark, Isabel Bermudez, Cecilia Gotti, Richard Sessions, Adrian Mulholland, Susan Wonnacott, Tim Gallagher

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Differentiating nicotinic acetylcholine receptors (nAChR) to target the high-affinity nicotine α4β2 subtype is a major challenge in developing effective addiction therapies. Although cytisine 1 and varenicline 2 (current smoking-cessation agents) are partial agonists of α4β2, these drugs display full agonism at the α7 nAChR subtype. Site-specific modification of (−)-cytisine via Ir-catalyzed C‒H activation provides access to C(10) variants 6–10, 13, 14, 17, 20, and 22, and docking studies reveal that C(10) substitution targets the complementary region of the receptor binding site, mediating subtype differentiation. C(10)-modified cytisine ligands retain affinity for α4β2 nAChR and are partial agonists, show enhanced selectivity for α4β2 versus both α3β4 and α7 subtypes, and critically, display negligible activity at α7. Molecular dynamics simulations link the C(10) moiety to receptor subtype differentiation; key residues beyond the immediate binding site are identified, and molecular-level conformational behavior responsible for these crucial differences is characterized. Molecular locksmithing is the use of precision chemical keys for biological locks. Nicotinic acetylcholine receptors (nAChR) associated with acetylcholine neurotransmission are linked to public health issues, notably tobacco addiction. Why is this important? Smoking kills seven million people annually and imposes a huge burden in terms of healthcare and lost productivity. The ability to design a molecule to achieve high receptor selectivity is paramount for the success of smoking cessation: poor selectivity is typically accompanied by (adverse) side effects. We have modified cytisine, a known “nicotinic activator,” in a very direct and versatile manner to suppress a particular characteristic: activation of the α7 subtype of nAChR. Computational molecular simulation of the protein-ligand complexes links these structural changes to a ligand's activity, facilitating the design of precision “molecular keys” for better discrimination of receptor subtypes and offering the potential of more targeted therapies. Efficient access to C(10) of (−)-cytisine via C‒H activation provides access to enantiomerically pure nicotinic acetylcholine receptor ligands that target the high-affinity nicotine α4β2 subtype with enhanced selectivity. These C(10) cytisine variants retain a partial agonist profile at the α4β2 subtype but, critically, display negligible activity at the α7 receptor subtype. Using computational methods, Gallagher and colleagues link receptor selectivity to key protein residues associated with, as well as beyond, the immediate ligand binding site.

Original languageEnglish
Pages (from-to)1710-1725
Number of pages16
JournalChem
Volume4
Issue number7
Early online date7 Jun 2018
DOIs
Publication statusPublished - 12 Jul 2018

Keywords

  • binding modes
  • CH activation
  • cytisine
  • iridium borylation
  • molecular dynamics
  • partial agonist
  • pyridone
  • SDG3: Good health and well-being
  • smoking cessation
  • α4β2 nicotinic receptor

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry
  • Environmental Chemistry
  • Chemical Engineering(all)
  • Biochemistry, medical
  • Materials Chemistry

Cite this

Rego Campello, H., Del Villar, S. G., Honraedt, A., Minguez, T., Oliviera, A. S., Ranaghan, K. E., ... Gallagher, T. (2018). Unlocking Nicotinic Selectivity via Direct C‒H Functionalization of (−)-Cytisine. Chem, 4(7), 1710-1725. https://doi.org/10.1016/j.chempr.2018.05.007

Unlocking Nicotinic Selectivity via Direct C‒H Functionalization of (−)-Cytisine. / Rego Campello, Hugo; Del Villar, Silvia G.; Honraedt, Aurelien; Minguez, Teresa ; Oliviera, A.Sofia; Ranaghan, Kara E.; Shoemark, Deborah; Bermudez, Isabel; Gotti, Cecilia; Sessions, Richard; Mulholland, Adrian; Wonnacott, Susan; Gallagher, Tim.

In: Chem, Vol. 4, No. 7, 12.07.2018, p. 1710-1725.

Research output: Contribution to journalArticle

Rego Campello, H, Del Villar, SG, Honraedt, A, Minguez, T, Oliviera, AS, Ranaghan, KE, Shoemark, D, Bermudez, I, Gotti, C, Sessions, R, Mulholland, A, Wonnacott, S & Gallagher, T 2018, 'Unlocking Nicotinic Selectivity via Direct C‒H Functionalization of (−)-Cytisine', Chem, vol. 4, no. 7, pp. 1710-1725. https://doi.org/10.1016/j.chempr.2018.05.007
Rego Campello H, Del Villar SG, Honraedt A, Minguez T, Oliviera AS, Ranaghan KE et al. Unlocking Nicotinic Selectivity via Direct C‒H Functionalization of (−)-Cytisine. Chem. 2018 Jul 12;4(7):1710-1725. https://doi.org/10.1016/j.chempr.2018.05.007
Rego Campello, Hugo ; Del Villar, Silvia G. ; Honraedt, Aurelien ; Minguez, Teresa ; Oliviera, A.Sofia ; Ranaghan, Kara E. ; Shoemark, Deborah ; Bermudez, Isabel ; Gotti, Cecilia ; Sessions, Richard ; Mulholland, Adrian ; Wonnacott, Susan ; Gallagher, Tim. / Unlocking Nicotinic Selectivity via Direct C‒H Functionalization of (−)-Cytisine. In: Chem. 2018 ; Vol. 4, No. 7. pp. 1710-1725.
@article{14e8e5b01e35478cbafc8b8a9e1a036f,
title = "Unlocking Nicotinic Selectivity via Direct C‒H Functionalization of (−)-Cytisine",
abstract = "Differentiating nicotinic acetylcholine receptors (nAChR) to target the high-affinity nicotine α4β2 subtype is a major challenge in developing effective addiction therapies. Although cytisine 1 and varenicline 2 (current smoking-cessation agents) are partial agonists of α4β2, these drugs display full agonism at the α7 nAChR subtype. Site-specific modification of (−)-cytisine via Ir-catalyzed C‒H activation provides access to C(10) variants 6–10, 13, 14, 17, 20, and 22, and docking studies reveal that C(10) substitution targets the complementary region of the receptor binding site, mediating subtype differentiation. C(10)-modified cytisine ligands retain affinity for α4β2 nAChR and are partial agonists, show enhanced selectivity for α4β2 versus both α3β4 and α7 subtypes, and critically, display negligible activity at α7. Molecular dynamics simulations link the C(10) moiety to receptor subtype differentiation; key residues beyond the immediate binding site are identified, and molecular-level conformational behavior responsible for these crucial differences is characterized. Molecular locksmithing is the use of precision chemical keys for biological locks. Nicotinic acetylcholine receptors (nAChR) associated with acetylcholine neurotransmission are linked to public health issues, notably tobacco addiction. Why is this important? Smoking kills seven million people annually and imposes a huge burden in terms of healthcare and lost productivity. The ability to design a molecule to achieve high receptor selectivity is paramount for the success of smoking cessation: poor selectivity is typically accompanied by (adverse) side effects. We have modified cytisine, a known “nicotinic activator,” in a very direct and versatile manner to suppress a particular characteristic: activation of the α7 subtype of nAChR. Computational molecular simulation of the protein-ligand complexes links these structural changes to a ligand's activity, facilitating the design of precision “molecular keys” for better discrimination of receptor subtypes and offering the potential of more targeted therapies. Efficient access to C(10) of (−)-cytisine via C‒H activation provides access to enantiomerically pure nicotinic acetylcholine receptor ligands that target the high-affinity nicotine α4β2 subtype with enhanced selectivity. These C(10) cytisine variants retain a partial agonist profile at the α4β2 subtype but, critically, display negligible activity at the α7 receptor subtype. Using computational methods, Gallagher and colleagues link receptor selectivity to key protein residues associated with, as well as beyond, the immediate ligand binding site.",
keywords = "binding modes, CH activation, cytisine, iridium borylation, molecular dynamics, partial agonist, pyridone, SDG3: Good health and well-being, smoking cessation, α4β2 nicotinic receptor",
author = "{Rego Campello}, Hugo and {Del Villar}, {Silvia G.} and Aurelien Honraedt and Teresa Minguez and A.Sofia Oliviera and Ranaghan, {Kara E.} and Deborah Shoemark and Isabel Bermudez and Cecilia Gotti and Richard Sessions and Adrian Mulholland and Susan Wonnacott and Tim Gallagher",
year = "2018",
month = "7",
day = "12",
doi = "10.1016/j.chempr.2018.05.007",
language = "English",
volume = "4",
pages = "1710--1725",
journal = "Chem",
issn = "2451-9294",
publisher = "Elsevier",
number = "7",

}

TY - JOUR

T1 - Unlocking Nicotinic Selectivity via Direct C‒H Functionalization of (−)-Cytisine

AU - Rego Campello, Hugo

AU - Del Villar, Silvia G.

AU - Honraedt, Aurelien

AU - Minguez, Teresa

AU - Oliviera, A.Sofia

AU - Ranaghan, Kara E.

AU - Shoemark, Deborah

AU - Bermudez, Isabel

AU - Gotti, Cecilia

AU - Sessions, Richard

AU - Mulholland, Adrian

AU - Wonnacott, Susan

AU - Gallagher, Tim

PY - 2018/7/12

Y1 - 2018/7/12

N2 - Differentiating nicotinic acetylcholine receptors (nAChR) to target the high-affinity nicotine α4β2 subtype is a major challenge in developing effective addiction therapies. Although cytisine 1 and varenicline 2 (current smoking-cessation agents) are partial agonists of α4β2, these drugs display full agonism at the α7 nAChR subtype. Site-specific modification of (−)-cytisine via Ir-catalyzed C‒H activation provides access to C(10) variants 6–10, 13, 14, 17, 20, and 22, and docking studies reveal that C(10) substitution targets the complementary region of the receptor binding site, mediating subtype differentiation. C(10)-modified cytisine ligands retain affinity for α4β2 nAChR and are partial agonists, show enhanced selectivity for α4β2 versus both α3β4 and α7 subtypes, and critically, display negligible activity at α7. Molecular dynamics simulations link the C(10) moiety to receptor subtype differentiation; key residues beyond the immediate binding site are identified, and molecular-level conformational behavior responsible for these crucial differences is characterized. Molecular locksmithing is the use of precision chemical keys for biological locks. Nicotinic acetylcholine receptors (nAChR) associated with acetylcholine neurotransmission are linked to public health issues, notably tobacco addiction. Why is this important? Smoking kills seven million people annually and imposes a huge burden in terms of healthcare and lost productivity. The ability to design a molecule to achieve high receptor selectivity is paramount for the success of smoking cessation: poor selectivity is typically accompanied by (adverse) side effects. We have modified cytisine, a known “nicotinic activator,” in a very direct and versatile manner to suppress a particular characteristic: activation of the α7 subtype of nAChR. Computational molecular simulation of the protein-ligand complexes links these structural changes to a ligand's activity, facilitating the design of precision “molecular keys” for better discrimination of receptor subtypes and offering the potential of more targeted therapies. Efficient access to C(10) of (−)-cytisine via C‒H activation provides access to enantiomerically pure nicotinic acetylcholine receptor ligands that target the high-affinity nicotine α4β2 subtype with enhanced selectivity. These C(10) cytisine variants retain a partial agonist profile at the α4β2 subtype but, critically, display negligible activity at the α7 receptor subtype. Using computational methods, Gallagher and colleagues link receptor selectivity to key protein residues associated with, as well as beyond, the immediate ligand binding site.

AB - Differentiating nicotinic acetylcholine receptors (nAChR) to target the high-affinity nicotine α4β2 subtype is a major challenge in developing effective addiction therapies. Although cytisine 1 and varenicline 2 (current smoking-cessation agents) are partial agonists of α4β2, these drugs display full agonism at the α7 nAChR subtype. Site-specific modification of (−)-cytisine via Ir-catalyzed C‒H activation provides access to C(10) variants 6–10, 13, 14, 17, 20, and 22, and docking studies reveal that C(10) substitution targets the complementary region of the receptor binding site, mediating subtype differentiation. C(10)-modified cytisine ligands retain affinity for α4β2 nAChR and are partial agonists, show enhanced selectivity for α4β2 versus both α3β4 and α7 subtypes, and critically, display negligible activity at α7. Molecular dynamics simulations link the C(10) moiety to receptor subtype differentiation; key residues beyond the immediate binding site are identified, and molecular-level conformational behavior responsible for these crucial differences is characterized. Molecular locksmithing is the use of precision chemical keys for biological locks. Nicotinic acetylcholine receptors (nAChR) associated with acetylcholine neurotransmission are linked to public health issues, notably tobacco addiction. Why is this important? Smoking kills seven million people annually and imposes a huge burden in terms of healthcare and lost productivity. The ability to design a molecule to achieve high receptor selectivity is paramount for the success of smoking cessation: poor selectivity is typically accompanied by (adverse) side effects. We have modified cytisine, a known “nicotinic activator,” in a very direct and versatile manner to suppress a particular characteristic: activation of the α7 subtype of nAChR. Computational molecular simulation of the protein-ligand complexes links these structural changes to a ligand's activity, facilitating the design of precision “molecular keys” for better discrimination of receptor subtypes and offering the potential of more targeted therapies. Efficient access to C(10) of (−)-cytisine via C‒H activation provides access to enantiomerically pure nicotinic acetylcholine receptor ligands that target the high-affinity nicotine α4β2 subtype with enhanced selectivity. These C(10) cytisine variants retain a partial agonist profile at the α4β2 subtype but, critically, display negligible activity at the α7 receptor subtype. Using computational methods, Gallagher and colleagues link receptor selectivity to key protein residues associated with, as well as beyond, the immediate ligand binding site.

KW - binding modes

KW - CH activation

KW - cytisine

KW - iridium borylation

KW - molecular dynamics

KW - partial agonist

KW - pyridone

KW - SDG3: Good health and well-being

KW - smoking cessation

KW - α4β2 nicotinic receptor

UR - http://www.scopus.com/inward/record.url?scp=85047789313&partnerID=8YFLogxK

U2 - 10.1016/j.chempr.2018.05.007

DO - 10.1016/j.chempr.2018.05.007

M3 - Article

VL - 4

SP - 1710

EP - 1725

JO - Chem

JF - Chem

SN - 2451-9294

IS - 7

ER -